Motif Bio to Present Iclaprim Data at ECCMID 2019
04 avr. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that four...
Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim
20 mars 2019 03h00 HE
|
Motif Bio plc
NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S....
Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board
18 mars 2019 03h00 HE
|
Motif Bio plc
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard...
Motif Bio Conference Call and Webcast
19 févr. 2019 02h00 HE
|
Motif BioSciences Inc.
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...
Motif BioSciences Enters into Amendment Agreement with Hercules Capital
18 févr. 2019 02h00 HE
|
Motif BioSciences Inc.
NEW YORK, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Motif...
Motif Bio Receives Complete Response Letter from the FDA
14 févr. 2019 02h00 HE
|
Motif BioSciences Inc.
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the...
Motif Bio to participate at upcoming Jefferies London Healthcare Conference
31 oct. 2018 03h00 HE
|
Motif BioSciences Inc.
NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the...
Motif Bio Presents New Iclaprim Data at IDWeek
03 oct. 2018 03h01 HE
|
Motif BioSciences Inc.
Iclaprim safety and efficacy in patients with wound infections in REVIVE Phase 3 trials NEW YORK, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage...
Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress
25 sept. 2018 02h00 HE
|
Motif BioSciences Inc.
NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD...
Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences
20 sept. 2018 02h00 HE
|
Motif BioSciences Inc.
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim...